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ABSTRACT 
 
Background and objectives: 
 
Patients with cirrhosis of liver according to current guidelines and  
recommendation need to undergo screening with an OGD scopy to  detect 
esophageal varices and to institute prophylactic measures in patients with large 
esophageal varices at the time of diagnosis and during follow up. This poses 
social and medical burden due to the greater number of cirrhotic patients and 
lesser number of endoscopy units. In this study we aim to identify the non 
invasive predictors of esophageal varices particularly fibroscan, spleen size, 
platelet count and platelet count/ spleen diameter ratio. 
Methods  
In this observational study of 50 patients, newly diagnosed patients with 
chronic liver disease without a history of gastro intestinal bleeding were 
included between march 2014 and September 2014. Relevant clinical 
parameters were assessed which included physical examination, complete 
hemogram, biochemical work up, liver stiffness measurement using fibroscan , 
USG measurement of spleen long axis diameter, OGD scopy . platelet count/ 
spleen diameter ratio was calculated for all patients. 
  
Results  
Among the 50 patients studied males predominated the study with 86%. 
Out of the study population 88% of the patients had varices. For a cut off point 
of fibroscan value > 32 ,the sensitivity  was 79.5% and specificity was 100% . A 
statistically significant correlation between fibroscan values and presence of 
varices  was noted ( P ==0.001). for a cut off value of platelet count/ spleen 
diameter the sensitivity was 68.2% and statistical correlation was sgnifican( P = 
for the prediction of varices. 
CONCLUSION: 
From our study we conclude that fibroscan is a valuable tool in the 
prediction of presence of  esophageal varices. But the cut off values differ from 
study to study which needs to be validated. A lower PC/SD ratio determine the 
presence of  highgrades of varices. From all these parameters we could identify 
the subset of patients who require OGD scopy for the prophylactic management 
of esophageal varices. Therefore  avoiding unnecessary endoscopy screenings 
and reducing the burden of endoscopy units. Apart from being non invasive 
these parameters are easily reproducible. 
Key words : Fibroscan, esophageal varices, chronic liver disease, platelet 
count to spleen diameter ratio, thrombocytopenia   
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INTRODUCTION 
 
Chronic liver disease is characterized by gradual destruction of 
hepatic tissue over time. The most common and deadly complication of 
chronic liver diseases is portal hypertension. Gastro esophageal varices, 
ascites, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary 
syndrome and hypersplenism develop as a consequence. 
The term portal hypertension was coined by Gilbert in 1902. 
However it was not until that Thompson could verify the increase in  
portal pressure directly during  laparotomy that portal hypertension was 
confirmed. It was way back in 1650 that Glisson at a dissection in 
London, established the portal vein as the vessel by which blood was 
collected from the gastrointestinal tract and returned to the systemic 
circulation. As early as 1543, Vlius drew an anatomical picture of the 
portal venous system.2 Variceal hemorrhage  is a life threatening 
complication with 20-30%  mortality rate being associated with every 
episode of bleeding2. 
The grade of esophageal varices often correlates with the severity 
of the liver disease. Around 40% of decompensated cirrhosis patients 
have varices during the time of diagnosis. 8% per year is the rate of  
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formation of varices and it develop during long term follow up in many 
patients. 
About 50% of cirrhotic patients develop gastroesophageal varices. 
5-33% of patients with portal hypertension develop gastric varices. The 
frequency of esophageal varices is 30-70% in cirrhotic patients  and 9-
36% of patients present with “high-risk” varices. 4-30%  of cirrhotic 
patients presenting with small varices would develop large varices every 
year and will be at risk of bleeding. 
Approximately 30% of patients with cirrhosis present with 
esophageal varices at the time of diagnosis, reaching 90% after 10 years. 
At 6 weeks the mortality rate of 20%is found due to bleeding from 
esophageal varices. Variceal bleeding is the most common fatal 
complication in cirrhotic patients.5 
The severity of liver cirrhosis can be assessed using CHILD –
PUGH score. Within the first year about 30% of patients with esophageal 
varices would bleed after diagnosis. The severity of the underlying 
disease will determine the mortality due to bleeding episodes. 
In such bleeding episode the resulting mortality may vary from  
<10% in compensated cirrhosis with child pugh score of A  to >70% in 
those patients with child pugh C advanced stage of cirrhosis. The risk of 
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re-bleeding is 80% within one year. Within 1-2 years after the index 
hemorrhage about 60% of patients who are not treated will develop “late 
– re-bleeding”. 
Around 1/3rd would re-bleed within 6 weeks of initial episode. 
Among these episodes 40% will take place within 5 days of initial 
episode of bleeding. 
Over the last decades clinical trials and research on animal models 
have evolved and led to current recommendations for management. 
Baveno V conference and AASLD GUIDELINES are considered for 
practical approach for management. Current recommendation  suggest 
that every patient who is newly diagnosed of cirrhosis should have an 
esophagogastroduodenoscopy  to look for the presence of varices and also 
the size of varices. Surveillance endoscopies are advised based on the size 
and presence of varices and the level of cirrhosis. 
For patients with compensated cirrhosis and NO varices –repeat 
endoscopy is recommended every 2-3 years. For patients with small 
varices OGD is repeated every 1-2 years. 
For patients with decompensated cirrhosis endoscopy is done at 
yearly intervals. 
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However this approach has 2  disadvantages 8. Endoscopy is a  tool 
which is invasive and cost effectiveness of OGD scopy is quite 
questionable since  9-36% of patients with chronic liver disease  are 
observed to have varices on OGD scopy . It may be better cost effective if 
only high risk beneficiaries undergo routine screening  for the presence of 
varices hence  as  reducing the inconvenience of patients and also OGD 
scopy units . there are factors that predict risk for initial episode of 
variceal hemorrhage. A lot of clinical, laboratory and USG  parameters 
are there when either as a single or in combination have good predictive 
power for non invasive assessment of risk of bleeding from varices. 
However these factors which predict the presence of varices are not 
defined clearly. 
 Acknowledgement of non invasive predicting tools of esophageal 
varices will be helpful for eveyone to perform OGD scopy in particular 
group of patients thus avoiding unwanted invasive procedures and 
expenditure, at the same time high risk patients are not missed with 
increased chances of hemorrhage. 
Currently many non invasive methods have been used to predict 
the presence of esophageal varices. Overall ,the most common result of 
these studies show that large spleen size, low platelet count, or their 
combination (platelet count to spleen diameter ratio),fibroscan ,portal 
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vein size or presence of collaterals on ultrasound, hypersplenism and 
child pugh score were the predictors of esophageal varices either directly 
or indirectly linked to portal hypertension.9 
In a study by Thomopoulus et al (2003) seventten variables 
considered relevant to the presence of esophageal varices were tested and 
came to conclusion that thrombocytopenia, splenomegaly and ascites are 
independent predicting tools of large esophageal varices in cirrhotic 
patients. The author gives suggestion that endoscopy could be avoided 
safely in cirrhotic patients with none of these predictive factors, as large 
varices are absent in this group of patients. 
Anyhow , in patients having a chronic liver disease the presence of 
Reduction in counts of platelets  may depend on many  factors other than 
portal hypertension ,like the  mean lifetime of the platelets may get 
reduced, synthesis of  thrombopoietin may be reduced, or marrow 
suppressive effects of ethanol or hepatitis viruses. On the other side, the 
evidence of  enlargement of spleen  in  patients with chronic liver 
diseases  is ultimately  the impact of  changes in the blood vessels that are 
usually linked  to portal hypertension. Having such idea  in mind, in the 
view of Gianni et al(2003),their study applied the platelet count /spleen 
diameter ratio to be a factor  associating reduction in platelet counts to 
13 
 
spleen size in an idea of  introducing  a factor that takes into account of 
the thrombocytopenia ,which is most likely depends on hypersplenism. 
According to Gianni et al (2003) by applying the platelet count/ 
spleen Size ratio might have put an end for performing  unwanted OGD 
scopy in every patients having a cut off  of > 909 not having the risk of 
going undiagnosed of  esophageal varices. 
More recently transient elstography (fibroscan) which estimates 
liver stiffness (LS) , has been a new method to diagnose esophageal 
varices with cirrhosis non invasively. While the accuracy of fibroscan in 
predicting clinically significant portal hypertension is good, its 
discriminative ability of predicting varices needs further validation. 
The combination of different methods may overcome the accuracy 
of single test by considering various pathophysiological components of 
portal hypertension. Recent study shows, the combination of 3    simple 
methods _ fibroscan, spleen size and platelet count proved to be of high 
accuracy in diagnosing and to rule out varices in patients with 
compensated hepatitis B virus related chronic liver disease. However data 
from Indian studies on fibroscan  for prediction of esophageal varices not 
much available.  
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Our study is aimed at the prediction of esophageal varices by using 
non invasive tools like fibroscan, spleen size and platelet count.  
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AIMS AND OBJECTIVES 
 
1. To study on the prediction of esophageal varices in chronic 
liver disease patients using fibroscan, spleen size and platelet 
count. 
2. To compare these non invasive markers with upper gastro 
intestinal endoscopy for the presence of varices. 
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REVIEW OF LITERATURE 
 
CIRRHOSIS  denotes a late stage of progressive liver fibrosis 
characterized by the development of regenerative nodules and distortion  
of  liver architecture.3 It is usually an irreversible process in the late stages 
at that point liver transplantation becomes the only left over option. 
Nonetheless in the earlier stages, cirrhosis is found to be a reversible 
process in various forms of hepatic disease.4  
Evolution of cirrhosis 10 
The typical  pathological features is a reflection of a chronic insult 
which cannot be reversed, to the hepatic  parenchyma, which is inclusive 
of  widespread  fibrosis along with formation of regenerative nodules. 
These features result from liver cell  necrosis, collapse of anchoring  
reticulin network with subsequent piling up of connective tissue  , 
destruction of vascular bed, and nodular regeneration of left over liver 
parenchyma. The pathological process should be considered  as a ultimate 
common pathway of many types of long standing  liver injury. Clinical 
features of cirrhosis derived from changes in the morphology and 
frequently a reflection of  the severity of  liver  damage rather than the 
causative factor  of the existing  liver disease. Lack of functioning liver 
cell tissue  may result in  jaundice, edema, bleeding diathesis, and a 
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variety of  metabolic alterations; fibrosis and collapsed  vasculature lead 
to portal hypertension and its consequences, including gastro esophageal 
varices and enlargement of spleen. Ascites and hepatic encephalopathy 
result from both liver cell  insufficiency and portal hypertension. 
Classification of cirrhosis12  
Three anatomical types of cirrhosis 
• Micronodular 
• Macronodular  
• Mixed  
Micronodular cirrhosis has characteristic feature of thick regular 
septae, regenerating tiny nodules with subtle change  in size and by 
involving each  lobule. 
Macronodular cirrhosis represented by impaired capacity for 
regrowth as in ethanol intake, malnutrition, older age or anaemia. 
Regenerative changes  in a micronodular cirrhosis results in 
macronodular or mixed architecture. In due course of time micronodular 
cirrhosis often gets converted into macronodular. 
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Etiology  
• Alcohol 
• Viral hepatitis types B ± delta, type C 
• Metabolic, eg; hemochromatosis, Wilsons, α1 antitrypsin 
deficiency, cystic fibrosis 
• Autoimmune hepatitis  
• NASH 
• Biliary cirrhosis :primary biliary cirrhosis, primary sclerosing 
cholangitis, autoimmune cholangiopathy 
• Cardiac cirrhosis 
• Cryptogenic cirrhosis 
• Indian childhood cirrhosis 
 
Diagnosis  of cirrhosis 
a) Clinical history: History of fatigue, easy bruising, pedal 
edema, fever, abdominal distension, abdominal pain, 
hemetemesis, malena,  high coloured urine, jaundice, weight 
loss, pruritus, altered sleep pattern or confusion. Risk factors for 
chronic liver disease like history of hepatitis, alcohol 
consumption, diabetes mellitus, drug intake, transfusion, family 
history of hepatic disorders and autoimmune disorders. 
 
b) Examination:  spider angioma, palmar eryhema, dupytrens 
contracture, gynecomastia, testicular atrophy, ascites, capud 
medusa, nail changes; muehrcke’s nails, terry nails, 
hepatomegaly, splenomegaly, icterus, fetor hepaticus, parotid 
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enlargement neurological changes: mental function , stupor, 
asterixis. 
 
c) Investigations : aminotransferase; aspartate and alanine, their 
ratio, alkaline phosphatase, gamma glutamyl transpeptidase, 
bilirubin, albumin, prothrombin time, INR ,serum  sodium, 
hematological abnormalities; anaemia, thrombocytopenia, 
leucopenia and neutropenia, serum immunological tests: 
hepatitis B antigen, anti HCV , alpha fetoprotein, smooth 
muscle antibodies, mitochondrial antibodies 
 USG 
By the use of USG ,cirrhosis is predicted by nodules on the surface 
of liver  and portal vein mean flow velocity. The caudate lobe becomes 
enlarged when compared  to the right lobe. Regenerative nodules can be 
visualized  as localised lesions.  
Computed tomography 
Computed tomography is economical for  diagnosing of cirrhotic 
patients and its complication. Any enlargement of the liver tissue can be 
measured and the irregular nodules on the surface is visualised. After I.V. 
contrast , the portal vein can be visualized  in the liver, and a collateral 
circulation with increase in size of spleen may give confirmation to the 
diagnosis of portal hypertension. Ascites can be identified. 
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Liver Biopsy 
It may be helpful to confirm the diagnosis. It is usually withheld in 
patients with alcoholic hepatitis and those who continue to consume 
alcohol until abstinence has been maintained for a minimum period of six 
months to determine the residual, non reversible disease. Sensitivity is 
around 80-100% and it depends upon the method used, and the size and 
number of specimens obtained. If the clinical, radiological and lab data is 
strongly suggestive of cirrhosis liver biopsy may not be needed. Eg; 
patient with ascites, nodular shrunken liver on ultrasound abdomen and 
with severe coagulopathy. Reticulin and collagen stains are essential for 
the demonstration of a rim of fibrosis around the nodule. 
EEG : it may be indicated if neuropsychiatric manifestations are 
present and to detect early changes in pre-coma. 
LIVER STIFFNESS MEASUREMENT 
A sonographic technique for assessing liver stiffness has been 
developed. Initial assessment suggest that it has good test characteristics 
in advanced fibrosis patients. 
MRI – its role in the diagnosis of cirrhosis remains unclear. 
NUCLEAR STUDIES: Radionucleotide studies are found useful 
in the diagnosis of cirrhosis.  
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STAGING  OF CIRRHOSIS 12 Recently a revised staging of 
cirrhosis classified  cirrhosis as compensated and decompensated. 
Decompensated cirrhosis is defined by the presence of 
complications secondary to portal hypertension: ascites, variceal bleeding 
and/or hepatic encephalopathy. 
Clinically patient may have fatigue, muscle wasting and weight 
loss. Gram negative bacteremia may produce mild fever which is often 
continuous. Other reasons for fever may be ongoing liver cell necrosis, 
continuing alcoholic hepatitis or complicating HCC. 
Asterixis may be present. Presence of jaundice denotes that hepatic 
cell destruction is exceeding the regenerative capacity and is viewed 
seriously. Intensity of jaundice is directly proportional to hepatic cell 
dysfunction. Other features are pigmentation of skin, purpuric spots over 
arms, shoulder and tibial shin and is an indicator of low platelet count, 
clubbing, spider angiomata, white nails, testicular atrophy, hepatomegaly, 
splenomegaly.  
Compensated cirrhosis11 is composed of two sub stages- without 
varices or with varices. In compensated patients without varices the 
development of varices and decompensation is predicted by the degree of 
portal hypertension. So compensated cirrhosis is further divided into 
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patients with clinically significant portal hypertension and without portal 
hypertension or portal hypertension which is not clinically significant. 
The diagnosis of decompensated cirrhosis is done clinically whereas sub 
staging of compensated cirrhosis  needs OGD scopy for diagnosing 
varices and HVPG measurement for estimation of portal pressure.  
Markers of cirrhosis are spider angiomata, palmar erythema , pedal 
edema, unexplained epistaxis, hepatomegaly, splenomegaly. Such 
patients remain in compensated stage until their death due to other cause. 
Precipitating factors for decompensation are bacterial infection, toxins, 
trauma or surgery. 
ASSESSMENT OF SEVERITY AND PROGNOSIS 
Severity may be measured by 
1. Child pugh scoring system 
2. MELD scoring system 
3. Liver biopsy 
Cirrhosis can be staged clinically. A reliable staging system is the 
modified child pugh classification with a scoring system of 5-15. This 
system was stipulated for risk stratification of patients before undergoing 
portal decompressive operation. 
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CHILD PUGH CLASSIFICATION 10, 
 
Child pugh classification 
 A 
1 point 
B 
2 points 
C 
3 points 
s. bilirubin  <2 2-3 >3 
s. albumin >3.5 2.8-3.5 <2.8 
Ascites  None Easily controlled Poorly 
controlled 
Prothrombin 
time(raise) 
INR 
0-4 
 
<1.7 
4-6 
 
1.7-2.3 
>6 
 
>2.3 
Encephalopathy  None Minimal Coma 
 
Child pugh score interpretation 
 
5-6      points: child score A 
7-9      points: child score  B                     
10-15  points: child score C                  
 
The child pugh score is a reasonably reliable predictor of survival 
in most of the hepatic disease and predicts the possibility of major 
complications of liver cirrhosis like variceal bleeding and spontaneous 
bacterial peritonitis. It has been used to assess the prognosis in cirrhosis 
and to provide the standard criteria for listing transplantation of liver. 
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MELD SCORE 13,17 
Recently the child pugh classification system has been replaced by 
MELD SCORE for assessing the necessity of liver transplantation. Model 
for end stage liver disease score is a prospective scoring system used for 
predicting the prognosis of hepatic disease and portal hypertensive 
patients. It is calculated by the use of 3 non invasive variables – serum 
creatinine, the prothrombin time expressed as INR and serum bilirubin 
model for end stage liver disease provide a more objective aspect to 
assess severity of the disease and has less variation with centre to centre 
than child pugh classification and the range of values are wider. Pediatric 
end stage liver system is a similar type of scoring system adopted for 
children <12 years.  
MELD =3.8[Ln serum bilirubin(mg/dl)] + 11.2[Ln INR] + 
9.6[Ln serum creatinine(mg/dl)] + 6.4 
 
SCORE THREE MONTH MORTALITY 
RATE(%) 
>40 71.3 
30-39 52.6 
20-29 19.6 
10-19 6 
<9 5 
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Other clinical settings  MELD score used are for predicting 
mortality in : alcoholic hepatitis, hepatorenal syndrome, fulminant hepatic 
failure, sepsis in cirrhosis, acute variceal bleeding, surgical procedure in 
CLD patients and TIPS procedure. 
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PORTAL HYPERTENSION10-13 
Portal hypertension is defined as the elevation of hepatic venous 
pressure gradient (HVPG) to >  5mm Hg.   
Clinically significant Portal hypertension : when portal pressure 
gradient increases above the threshold value of 10 mmHg or 12 mmHg 
,portal hypertension is known to be clinically significant. Portal pressure 
gradient values between  six and ten mmHg known as subclinical portal 
hypertension. 
Portal pressure gradient is calculated  by the product of vascular 
resistance inside the portal venous system and blood flow.   
Portal pressure is calculated clinically by hepatic venous pressure 
gradient( HVPG) measurement. 
HVPG is the difference between wedged hepatic venous pressure 
and free hepatic venous pressure. 
HVPG  exactly reflect the portal pressure in viral cirrhosis and 
alcoholic cirrhosis. 
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ANATOMY 
The confluence of splenic vein and superior mesenteric vein forms 
the portal vein , behind the neck of pancreas. The length of portal vein is 
about 7.5 cm . it runs into the hilum of liver, posterior to the bile duct and 
hepatic artery. The portal vein gets divided into a right branch and a left 
branch in the hilum of liver . these branches supply right side of the liver 
and left side of the liver respectively. The portal venules get drained into 
liver sinusoids, then hepatic veins drains into inferior vena cava. 
Liver  has a low resistance and a high compliance system of 
circulation which is capable to accommodate a very large volume of 
blood without increase in portal pressure substantially. Liver has double 
blood supply in the form of portal vein and hepatic artery which 
constitutes of 30% of cardiac output. Venous blood from portal veins 
forms around 75% of total blood flow in the liver. 
Convergence of blood derived from portal vein and hepatic artery 
takes place in a special blood channel which is highly compliant known 
as hepatic sinusoids. 
Hepatic arterial buffer response is a autoregulatory mechanism 
which maintains the total blood flow  of the liver at constant level. 
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ANATOMY OF FORMATION OF PORTAL  VEIN 
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Portal vein communicate with systemic veins at 5 points 
1. At the gastro esophageal junction( cardia) 
2. In anal canal formed between superior hemorrhoidal vein and 
middle hemorrhoidal veins 
3. Between para umbilical veins and the veins that drain the 
abdominal wall at region of falciform ligament 
4.  Between venous bed of the spleen and the left renal vein 
5. In the retroperitoneum 
Great clinical importance lies at gastro esophageal junction from 
which varices develop. 
At the gastro esophageal junction a 4 well defined zones  of the 
intrinsic veins  are formed. They are  
1. Gastric zone  
2. Palisade zone 
3. Perforating zone 
4. Truncal zone 
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Gastric zone 
It consists of a radially arranged band of veins in lamina propria 
and submucosa and is a 2-3 cm zone whose upper border lies at the gastro 
esophageal junction. 
 
Palisade zone 
Is  a direct continuation of gastric zonal veins which takes origin at 
GE junction  and run in palisading fashion or array of veins which are 
longitudinally packed in the region of lamina propria. They form the 
primary site of inter communication between the azygous and the portal 
bed. 
 
Perforating zone 
Is  a 2-3 cm cranial extension of the palisade zone. The primary 
drainage of intrinsic veins into the extrinsic veins through the perforating 
veins which ahs valves. It normally permit uni directional flow. 
 
Truncal zone 
Is  an eight to ten cm zone which continues from the perforating 
zone in an upward fashion. The intrinsic veins are made up of 3-4 large 
trunks of veins at the region of submucosa. It has a communication 
venous plexus of submucosal region. The direction of flow of is in a 
cranial to caudal fashion through the perforating veins into extrinsic 
venous channels. 
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In the situation of portal hypertension as an adaptive response 
increase in flow occurs to pump blood into the heart via the 
communication of porto systemic circulation. The intrinsic veins in and 
around the GE junction gets dilated and turns tortuous and they form 
varicose veins. 
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PORTOSYSTEMIC COMMUNICATIONS 
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PATHO PHYSIOLOGY OF PORTAL HYPERTENSION 
Portal hypertension is considered as one of the major complication 
of liver cirrhosis. Portal venous pressure greater than  12 mmHg is 
associated with development of clinical features or complication of 
cirrhosis of liver. 
 
Normal physiology13 
The passage of portal blood across the hepatic tissue depends 
mainly on the pressure gradient among the hepatic veins and the portal 
veins. Hepatic venous pressure is a reflection of central venous filling 
pressure. The product of blood flowing through the portal veins and the 
vascular resistance determines the portal pressure.  
Portal pressure = portal blood flow x vascular resistance 
The difference between the hepatic venous pressure and the portal 
venous pressure does not raise above 4 mmHg , under normal 
circumstances. In order to maintain the hepatic pressure gradient in a 
normal range ,the liver acts as a reservoir of blood.  
To accommodate any alteration like increase in outflow pressure, 
the hepatic sinusoids are recruited in large numbers. Hence any elevation 
in hepatic venous pressure does not cause increase in portal pressure in 
similar manner. 
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Liver sinusoids acts as major site of resistance for portal 
vasculature. 
The sum of the blood flow from the three major  splanchnic 
tributaries forms Portal venous inflow. 
In an normal individual 600- 1200 ml/ min is the normal portal 
inflow which is measured by Doppler flowmetry intra operatively. 
The vascular resistance of the arteries of splanchnic circulation 
regulates the portal flow volume21. In case of physiological events like 
during postprandial state or any postural change, alteration of arteriolar 
resistance of splanchnic circulation will result in alteration of portal 
inflow. Somatostatin which is an inhibits many GI hormones which might 
mediate the arteriolar vasodilatation can be pre administered to prevent 
any rise in portal pressure after a meal. After a meal an increase in AV 
extraction of oxygen will result in reduction of oxygen content of the 
portal venous system. 
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HEMODYNAMICS IN PORTAL HYPERTENSION 
 
Vascular resistance22  
The development of portal hypertension is the result of rise in 
vascular resistance of portal circulation  and this forms the basis of 
classification of portal hypertension. The combination of measurement of 
hepatic vein pressure and portal venous pressure gives an idea of site of 
vascular resistance in cirrhosis of liver. In  non alcoholic cirrhosis many 
measurements will result in high pressure in portal veins when compared 
to hepatic venous wedge pressure.  
This is an indication of existence of a pre sinusoidal component 
which may be related to the fibrotic changes or inflammation in the portal 
triads. Since the hepatic and portal venous wedge pressures remain same 
in alcoholic cirrhosis, the vascular resistance should lie at the level of 
sinusoids.      
In case of alcoholic cirrhosis there lies a controversy in the 
pathogenesis of increase in sinusoidal resistance. Increase in sinusoidal 
resistance may be due to  
• Presence of collagen in the space of Disse 
• Los of fenestration in the sinusoids 
• Existence of contractile myo fibroblasts 
•  Low resistance channel may become capillarized 
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In alcoholic liver disease a relationship between intrahepatic 
pressure and size of the hepatocyte was observed for a mild to moderate 
rise in pressure. A complex relationship lies between these factors in case 
of non alcoholic cirrhosis.23 
Portal blood flow and systemic circulation  
Two models are enlisted tin order to explain the changes of portal 
blood flow with response to PHT. The hypotheses are 
¾ Backward flow hypothesis 
¾  Forward flow hypothesis 
 
Backward flow hypothesis 
Is  based on the fact that an increase in portal venous pressure 
which may trigger a myogenic response which in turn may decrease 
inflow into thesplanchnic arteries. Portal pressure will  revert to normal as 
a result of this. The backward component may contribute to the 
maintenance  of PHT even when it is established fully. 
Forward flow hypothesis  
The  maintenance of portal hypertension is due to the paradoxical 
rise in portal inflow. Portal hypertension is a unique hemodynamic 
syndrome to exhibit both increase in resistance and increased inflow. 24-28 
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The major factors which lead to fall in systemic vascular resistance 
are decrease in muscular arterial resistance and the resistance in the 
splanchnic circulation. 
In various forms of portal hypertension a  hyperdynamic 
circulatory state is observed. Peripheral vasodilatation may be due to 
humoral fectors. A rise in glucogan values is observed in the presence of 
PHT and porto systemic shunts. Prostaglandins, endotoxin mediated 
activation of NO, prostacyclin and bile salts are the other probable 
humoral factors.  
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VASCULAR DISTURBANCES IN PORTAL HYPERTENSION 
AND SITES OF ACTION OF DRUGS 
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PORTAL HYPERTENSION AS A HEMODYNAMIC SYNDROME 
Splanchnic  hemodynamics 
¾ Increase in resistance of portal vasculature 
¾ Increase in portal venous inflow 
¾ Porto systemic shunting 
 
Systemic hemodynamics 
¾ Arterial vasodilatation 
¾ Increase in plasma volume 
¾ Reduction in systemic vascular resistance 
¾ Increase in cardiac output 
¾ Reduction in mean arterial pressure 
¾ Rise in heart rate 
Regional blood flows 
¾ Reduction in cerebral blood flow 
¾ Increase in blood flow to muscles 
¾  Variations in  blood flow to kidneys 
  
Alterations in the blood flow volume can produce alterations in 
vascular resistance of the collateral bed. An increase in blood flow may 
increase diameter of the vessel and a decrease in blood flow may result in 
reverse changes with a small vessel which offers an rise in resistance to 
flow.  
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In a non distensible vessel the resistance to the flow of fluid is 
related to  
• The length of the vessel 
• Viscosity of the fluid 
• Inversely related to further power of the radius 
 
Which leads to affect the resistance to flow markedly even during 
minimal changes in diameter of the vessel [ poiseuille’s law ] 
Resistance = 8nlπr4 
Many drugs used in the treatment of PHT decrease portal pressure 
by decreasing the portal blood flow. The relationship among vessel flow 
and the radius of the vessel has been delineated denotes that a decrease in 
flow may lead to increase in vascular resistance. This is a significant 
principle in the drug therapy of portal hypertension.25 
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VASODILATOR AND VASOCONSTRICTOR MOLECULES 
IMPLICATED IN THE VASCULAR ABNORMALITIES IN 
PORTAL HYPERTENSION 
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RUPTURE OF ESOPHAGEAL VARICES28-32 
The exact mechanism by which esophageal varices get ruptured 
has not been fully elucidated. 
The “ corrosion hypothesis”  States  that injury to the mucosa of 
the esophagus at the lower part with consequent erosion into the 
submucosal varices is due to the reflux of gastric acid. 
Limitation : failure to exhibit the evidence for raised gastro 
esophageal reflex  by measuring pressure at lower esophageal sphincter 
and pH. 
Explosion hypothesis 
  States that esophageal rupture occurs when the vessel wall tension 
reaches a critical level. 
A relationship between variceal pressure and bleeding risk has 
been documented by measuring variceal pressure by means of endoscopic 
capsule. 
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IMPACT OF PORTAL HYPERTENSION ON OTHER ORGANS 
Hypersplenism  can occur in spite of absence of splenomegaly. Others 
are   
9 Variation  in the microcirculation the spleen 
9 Splenic sinusoids undergo fibrotic changes 
9 Entrapment of RBCs, white blood cells, platelets 
  
Bonemarrow:  remains active. In the absence of other factors that 
can cause alteration in platelet count like alcohol, drugs, 
thrombocytopenia is an indicator of portal hypertension. 
Hypoxemia  is an usual finding with partial pressure of arterial 
oxygen in the range of 60- 80 mmHg. The basic problem lies in the 
Pulmonary AV  shunting Pulmonary hypertension  may develop in some 
of the patients irrespective of the etiology of portal hypertension. 
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CLASSIFICATION OF PORTAL HYPERTENSION 
 
PRE HEPATIC 
 Portal vein thrombosis 
 Splenic  vein thrombosis 
 Banti’s syndrome ( massive splenomegaly) 
 
HEPATIC  
Pre sinusoidal 
  Schistosomiasis 
 Congenital hepatic fibrosis 
Sinusoidal 
 Cirrhosis – many causes 
 Alcoholic hepatitis 
Post sinusoidal 
 Veno occlusive syndrome 
 
POST HEPATIC  
  Budd chiari syndrome 
 Inferior vena caval webs 
 Cardiac causes – restrictive cardiomyopathy, CCF                     
Constrictive pericarditis 
Prehepatic    causes are those entities which affect the portal 
venous system before entering into the liver. 
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CLASSIFICATION OF PORTAL HYPERTENSION 
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Posthepatic   causes are those entities which interfere with hepatic 
veins and venous drainage to the cardiac tissue. 
Intrahepatic  causes contribute to more than 95% of cases of portal 
hypertension , represented by common forms of cirrhosis. 
COMPLICATIONS 
Three major complications are gastro esophageal varices , ascites and 
hypersplenism. so patients present with 
 Hemetemesis, malena 
 Abdominal distension , pedal edema 
 Splenomegaly 
 Thrombocytopenia 
 Leucopenia  
 
Physical examination 
  May provide some clues to the differential diagnosis.  
In the setting of variceal hemorrhage , always  cirrhosis should not 
be presumed and other etiology such as pre sinusoidal may be taken into 
account. But pre sinusoidal etiology can be considered less likely if 
patient present with portal hypertension and ascites, until 
hypoalbuminemia may alter the relationship of hydrostatic pressure and 
the oncotic pressure of the capillaries of the intestine. 
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Liver size   
Offers  clues to narrow down the etiology. In the presence of portal 
hypertension a small  liver suggests hepatic cirrhosis. Consistency of liver 
edge if it is found to be normal, it can less likely to be a sinusoidal 
etiology. 
Venous hum 
  Excludes  portal vein thrombosis if it is present in the peri 
umbilical area which indicates high flow via aa patent umbilical vein. 
IMAGING OF THE PORTAL VENOUS SYSTEM 10-13 
CHEST RADIOGRAPHY  
An enlarged and distended azygous vein may present in chest x ray 
which may be interpreted as a mass in right hilar area or there may be an 
enlarged pulmonary arteries. 
ANGIOGRAPHY 
Angiography of the mesenteric vessels may give some 
physiological and anatomical data. Splenoportography provides excellent 
anatomical detail but rarely used because of risk of puncture to the 
spleen. 
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ULTRASONOGRAPHY 
An enlarged portal vein may be suggestive of portal hypertension. 
If collaterals are visualized it may confirm the presence of portal 
hypertension. 
DOPPLER ULTRASONOGRAPHY 
Doppler ultrasonogrphy may portray the anatomical details of the 
hepatic artery and the portal vein. 
It may depicts the spontaneneous hepato fugal flow in the portal 
vein, splenic vein and superior mesenteric vein in cirrhotic patients.  
If the flow is in ahepato petal direction there may be a possibility 
of variceal hemorrhage. 
COMPUTED TOMOGRAPHY 
A contrast CT scan may portray the patency of the portal vein ane 
the esophageal varices as an protruding intraluminal shadows which gets 
enhanced after a contrast. 
Gastric varices may be  seen as rounded structures which are not 
differentiated from the gastric wall. 
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The venogram shows a wide variation in the presence of cirrhosis 
“Tree in winter appearance” – filling of large collateral vessels with 
distortion of intra hepatic pattern grossly. 
 
                   
 
Ultrasonography  shows a patent portal vein( P); arrow indicates 
inferior vena   cava 
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COLOUR DOPPLER ULTRASONOGRAM OF THE PORTA 
HEPATIS SHOWS THE HEPATIC ARTERY IN RED AND 
PORTAL VEIN IN BLUE 
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SCREENING FOR VARICES 
All  cirrhotic patients should undergo screening for esophageal 
varices in order to provide prophylactic treatment to those patients who 
are at increased risk of hemorrhage. 
RATIONALE:  
Improved    clinical outcomes are observed with identification and 
treatment of patients with high risk varices. 
At the time of diagnosis 30% of compensated cirrhotic patients and 
60% of decompensated cirrhotic patients  found to have varices. 
Among the patients with varices, 12% is the annual rate of first 
bleeding episode and the mortality rate after each episode of bleeding is 
15 – 20 %. 
SCREENING  METHODS 
 OGD scopy : it is the gold standard method 
 
 VIDEO CAPSULE ENDOSCOPY 
 
Screening is repeated every 2 – 3 years in compensated cirrhotic 
patients who do not present with varices. Screening is repeated every year 
or at the time of 1st decompensation in patients with decompensated 
cirrhosis. 
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PARAMETERS ASSESSED  are 
a) Number of varices 
b) Appearance 
c) Size of esophageal varices 
d) Presence of red color  signs 
 
CLASSIFICATION OF VARICES4 
 F1: Small, Straight Varices 
 
 F2: enlarged , tortuous varices  that occupy < 1/3rd of the lumen 
 
 F3: large, coil-shaped varices that occupy > 1/3rd of the lumen 
 
Many  hepatologists and endoscopist categorize varices as either 
large or small, since medium sized varices F2  are managed same way as 
large varices F3.  
PROGRESSION OF VARICES 23-28 
The rate of development of and progression of esophageal varices 
has not been evaluated extensively in cirrhotic patients. Based on a 
clinical trial the following were noted from annual endoscopy. 
 New varices develop in 5 %  at one year, 28% at the 3rd year 
 
  Small varices progressed in size at a rate of 12% in 1st year and 
 
 31% in 3rd year 
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 Progression was predicted by child pugh score, presence of red 
wale signs on the 1st examination and an alcoholic cause of 
cirrhosis 
 
 The 2 year risk of bleeding was significantly high in patients with 
small varices than without varices. 
 
 For patients with compensated cirrhosis and NO varices –repeat 
 endoscopy is recommended every 2-3 years. For patients with 
small 
 varices OGD is repeated every 1-2 years 
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VARICEAL BLEEDING 
Active variceal bleeding accounts for about 1/3rd of all deaths 
related to cirrhosis.  There are 4 major issues with respect to prevention 
and treatment of variceal bleeding 
 
  Prediction of at risk patients 
 
  Prophylaxis against a 1st episode of bleed 
 
 Treatment of active bleed 
 
 Prevention of re bleeding 
 
PREDICTIVE FACTORS 12 
¾ Location of varices 
 
¾ Size of varices 
 
¾ Appearance of varices 
 
¾ Clinical features of the patient 
 
¾ Variceal pressure 
 
Location of varices: 
The most common sites are distal end of esophagus, stomach, 
rectum. Varices arise deep within the submucosa in the mid esophagus 
but becomes superficial at the distal end of esophagus. 
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Size of the varices 
The risk of variceal hemorrhage correlates independently with 
diameter of the varix. 
Appearance of varices 
RED SIGNS 
¾ Red wale marks: longitudinal red coloured streaks on 
varices that are similar to red corduroy wales 
¾ Cherry red spots : discrete red cherry coloured spots which 
are flat and lie above the varices 
¾  hematocystic spots : elevated discrete spots that are 
similar to blisters 
¾ Diffuse erythema: diffuse red color of varix 
Clinical features 
¾  Degree of hepatic dysfunction 
 
¾ History of previous variceal hemorrhage 
 
Variceal pressure 
The incidence of variceal hemorrhage with different variceal pressure 
levels are 
¾ <13 mmhg      – 0% 
¾ >13 mmhg      – 9% 
¾ >14- 15mmhg – 17% 
¾ >15- ≤16 mmhg – 50% 
¾ >16 mmhg -  72%  
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PRIMARY AND PRE- PRIMARY PROPHYLAXIS 35-39 
Pre  primary prophylaxis 
   Aims  at preventing the development of varices in patients with 
portal hypertension who have not yet developed varices. These patients 
are to be routinely screened for detecting development of varices. 
Primary prophylaxis  
Refers to the prevention of first variceal bleeding in a patient with 
varices. The approaches are 
PHARMACOLOGICAL PROPHYLAXIS:32-36 
Using a non selective beta blocker propronolol and nadolol. The 
goal of drug therapy is to reduce the portal venous inflow. These non 
selective beta blockers will block the adrenergic dilatory tone in 
mesenteric arterioles, which results in unopposed alpha mediated 
vasoconstriction which results in reduction of portal inflow.  
The dose of NADOLOL : 40 mg per day 
PROPRANOLOL : 20 mg twice daily 
Propranolol produce a 9 -23% reduction in HVPG. 
DOSE TITRATION  for these drugs are achieved by 
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a) Titrating resting heart rate- to achieve arresting heart rate of 55 
– 60 beats per minute. 
b) HVPG : A  decrease in HVPG below 12 mmhg probably 
eliminates the risk of variceal bleed. 
ENDOSCOPIC PROPHYLAXIS 
Using endoscopic variceal ligation 
The general approach based on Baveno consensus and AASLD 
guidelines, the prophylaxis is given to patients with 
¾ Small varices with red signs or child B or C  cirrhosis 
 
¾ Medium or large varices 
 
EVL eradicates esophageal varices with fewer complications than 
 endoscopic sclerotherapy. 
Complications associated are bleeding from banding induced 
ulcerations. So  EVL should be done by an endoscopist with expertise in 
prophylactic banding. 
Approaches that are not advised for primary prophylaxis are 
¾ Endoscopic sclerotherapy 
¾  Surgical portal decompression  
¾ Transjugular  intrahepatic porto systemic shunts 
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TREATMENT OF ACTIVE VARICEAL HEMORRHAGE 
 
The current treatment options available are  
¾  Pharmacological therapy 
¾ Endoscopy 
¾ Surgery 
¾ TIPS procedure 
 
GENERAL PRINCIPLES OF SUPPORT 
¾  Transfusion 
 Prevention of aspiration 
¾  Use of recombinant factors 
 
PROPHYLACTIC ANTIBIOTICS 
Cirrhotic patients presenting with upper GI bleeding should be 
given prophylactic antibiotic preferably before endoscopy.  
The AASLD guidelines recommend the use of  
¾  Oral norfloxacin 400mg twice daily 
 
I.V. Ceftriaxone  1g/ day is preferred in centres with quinolone 
resistant organisms. 
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INTRAVENOUS VASOPRESSIN AND ITS ANALOUGS 
a) Vasopressin : dose 0.4 u bolus followed by 1 unit/ min infusion . it 
directly constricts mesenteric arterioles and reduces portal venous 
inflow and reduces portal pressure. 
Limitations :  
¾  will not improve survival from active hemorrhage 
¾ Has very minimal effects on early rebleeding episodes 
¾ Extra splanchnic vasoconstrictor property 
 
b) Terlipressin : synthetic analog of vasopressin, released in slow and 
sustained manner 
Dose : 2 mg IV every 4th hourly titrated to 1 mg every 4th hourly 
once bleeding is controlled.  
SOMATOSTATIN AND ITS ANALOGS 
Somatostatin  causes inhibition of the liberation of glucogon, 
causing indirect vasoconstriction of splanchnic circulation and reduces 
portal blood flow. Since somatostatin is not widely available , its analog 
is used. 
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OCTREOTIDE 
Long acting analog of somatostatin .  
Given as 50 mcg bolus IV followed by 50 mcg per hour infusion 
and continued for 3 – 5 days. 
ENDOSCOPIC TREATMENT 
It is currently the definitive treatment of choice for active variceal 
bleeding. 
Two forms commonly used are 
 Sclerotherapy:  injection of sclerosant solution into the varices 
through an injection needle that is placed through the endoscope 
using freehand technique. 
 Variceal Band Ligation:  it involves placing of elastic bands 
around the varices in the distal 5cm of esophagus. 
FAILURE OF ENDOSCOPIC THERAPY 
Defined as mortality or necessity to change treatment defined by 
 New episode of blood vomiting or Ryles tube aspiration of greater 
than or equal to100ml of fresh blood. More than or equal to 2 hours 
after the initiation of particular drug therapy or therapeutic  
Endoscopy 
  Development of hypovolemic shock 
 3 g fall in hemoglobin during  any 24 hour duration  if no 
transfusion is done. 
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BALLOON TAMPONADE 
It is reserved for temporary stabilization of patients until more 
definitive treatment can be instituted. 
3 balloons has been used 
  Sengstaken – blackmore tube 
 Minnesota tube 
 Linton-nachias tube 
Initial control of bleeding has been achieved in 30 – 90% of 
patients. 
Major limitation: rebleeding following deflation. 
 
SURGERY 
Ideal patient for surgery : one with preserved liver function who 
fails emergent endoscopic treatment and has no complications from the 
bleeding or endoscopy. 
TYPES OF SURGERY42 
SHUNT OPERATIONS 
Categorized as  
¾ Non selective : portocaval shunts 
¾ Selective   : distal splenorenal shunt 
¾ Partial  
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NON SHUNT OPERATIONS 
¾ Esophageal transaction 
¾ Devascularisation  of gastroesophageal junction – suglura 
procedure 
 
TRANSJUGULAR INTRAHEPATIC PORTO SYSTEMIC 
SHUNTS 
A  TIPS  is created by passing needle catheter via the transjugular 
route into the hepatic vein and wedging it there. The needle is then 
extruded and advanced through the liver parenchyma to intrahepatic 
portion of tha portal vein .  It is indicated for patients with uncontrolled 
variceal bleeding despite combined drug therapy and endoscopic therapy. 
RECURRENT VARICEAL BLEEDING 
AASLD GUIDELINES 
  Cirrhotic patients who survive an episode of active variceal  
bleeding should get therapy for secondary prophylaxis 
 Combination of non selective beta blockers and endoscopic 
variceal ligation is the best method  for secondary prophylaxis 
 EVL should be done once in 1 to 2 weeks till it gets obliterated 
  TIPS  should be considered in patients with child A or B cirrhosis 
and underwent  recurrent hemorrhages inspite of  combination of 
drug therapy and endoscopic treatment. 
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 Patients who are eligible to undergo transplatation   should be 
referred to a  centre with facility for transplantation.   
NON INVASIVE  PARAMETERS FOR PREDICTION OF 
ESOPHAGEAL VARICES 
Studies have attempted to identify parameters that non invasively 
predict the presence of esophageal varices. 
Overall the most common results of these studies , the parameters 
are  splenomegaly  and  thrombocytopenia. 
More recently transient elastography (fibroscan) which estimates      
liver   stiffness(LS) , has been a new method to diagnose esophageal  
varices with cirrhosis non invasively. While the accuracy of fibroscan in 
predicting clinically significant portal hypertension is good, its 
discriminative ability of predicting varices needs further validation. 
In a study by Thomopoulus et al(2003) seventeen variables 
considered relevant to the presence of esophageal varices were tested and 
came to conclusion that thrombocytopenia, splenomegaly and ascites are 
independent predictors of large esophageal varices in cirrhotic patients. 
The author suggest that OGD scopy could be withheld safely in cirrhotic 
patients with none of these predictive factors, as large varices are absent 
in this group of patients. 
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Sharma SK et al49 in a prospective study took account of patients 
who are diagnosed for the first time with cirrhosis and no history of 
hemorrhagic episodes were scheduled to subjected for OGD scopy. Of 
the 101 patients (median age 45; range 15-74 years; 87 male; Child-Pugh 
class: A 18, B 31, C 52), 46 had LEV. On univariate analysis, 5 variables 
were significantly associated with thepresence of LEV. These included 
anaemia (P = 0.026), splenomegaly(P= 0.009), platelet count (P < 0.002), 
total WBC count (P0.0004) and liver span on ultrasound (P = 0.031). On 
multivariate analysis, 2 of these parameters,  thrombocytopenia and 
splenomegaly, were identified as independent predictors of the presence 
of LEV. The conclusion made was that presence of splenomegaly and 
thrombocytopenia are independent predictors of presence of LEV in 
cirrhotic patients. With the help of these parameters, may identify patients 
with a low probability of LEV who may not need UGIE. This may help 
decrease economic burden and displeasure for these patients and the 
workload of OGDscopy units.49 
Zaman A et al47 studied ninety-eight patients without a history of 
variceal hemorrhage underwent esophago gastroduodenoscopy as part of 
a liver transplant evaluation. The etiology of cirrhosis among the 67 men 
and 31 women (mean age, 48 yr) included 28% viral HepatitisC infection 
,ethanol consumption, 25% viral Hepatitis C, 13% , 9% primary 
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sclerosing cholangitis/primary biliary cirrhosis, 9% cryptogenic, 6% 
Hepatitis B, 1% Hepatitis B and C, and 9% other. 
Patients were Child-Pugh class A 34%, B 51%, and C 15%. 
Endoscopic findings included esophageal varices in 68% of patients (30% 
were large), gastric varices in 15%, and portal hypertensive gastropathy 
in 58%. 
Platelet count <88,000 was the only parameter identified by 
univariate/multivariate analysis (p < 0.05) as associated with the presence 
of LEVs (odds 55 ratio 5.5; 95% confidence interval 1.8-20.6) or gastric 
varices (odds ratio 5; 95%confidence interval 1.4-23). Platelet count 
<88,000 is associated with the presence of esophagogastric varices. A 
large prospective study is needed to confirm and validate these findings 
and may allow identification of a group of patients who would most 
benefit from OGD scopy screening for varices. 
RELEVANCE OF PLATELET COUNT/SPLENIC DIAMETER 
RATIO 
 
Gianni et al (2003)54 made a proposal that ratio of PC/SD ratio, as a 
non invasive tool for prediction of  esophageal varices in patients with 
chronic liver disease. 
In the study done by Gianni et al the largest diameter of spleen  
was Calculated  with the help  of ultrasonography  and was read  in 
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millimetres (mm).the  ratio of  PC/SD   of all patient was computed. The 
results were that  diameter  of the splenic tissue was larger while PC/SD 
ratio was smaller value in patients with esophageal varices. Receiver 
operating characteristic curve (ROC curves) were 56 applied to tabulate 
the PC/SD ratio cut off  which may give the results of the best sensitivity 
and specificity in diagnosing of esophageal varices (cut off=909, 
sensitivity=100% (95% CI 100–100); specificity=93% (95% CI 82–98)). 
The prevalence adjusted positive and negative predictive values 
were 96% and 100% corresponding, for a ratio of PC/SD  of 909. 
furthermore , accuracy of the ratio of PC/SD  cut off  value as calculated 
by the c index was 0.981 (95% CI 0.943– 0.996). 
Gianni et al (2003)54  stated   that the application of this ratio is of 
significant and is useful , and this hypothesis can be given support by a 
numerable clinical and statistical causes. 
However  , the value of the PC/SD ratio overcome this probable 
disadvantage because it "normalizes" platelet count to splenic 
sequestration, invariably  representing the aliquot of reduction in platelet 
count resulting from portal hypertension. 
Moreover , from a statistical point of consideration, the PC/SD  
ratio was the one variable independently associated with the presence of 
esophageal varices. 
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The study suggested  that the value of the platelet count/spleen 
diameter ratio may  avoid conducting  OGD scopy that is not needed in 
all patients with a cut off >909 without meeting the risk of  undiagnosed 
of esophageal varices. It is cost benefit also.  
According to Gianni et al (2005)64 after the 1st OGD scopy, the 
value of the PC/SD ratio found as an efficient  means for identification of 
the presence of oesophageal varices  in the longitudinal follow-up of 
cirrhotic patients also. 
WW Baig et al65  conducted a study involving 150 patients of 
chronic liver diaease by making use of Lab  and USG parameters  as a  
prospective study. The platelet count/ spleen diameter  ratio in patients 
with  esophageal varices were statistically significant. 
Abu El Makarem MA et al conducted a prospective study from that 
they cocluded that the platelet count/ bipolar spleen diameter ratio has 
excellent accuracy in the non invasive assessment of EVs in cirrhotic 
patients. 
 
RELEVENCE  OF FIBROSCAN 55 – 59 
FIBROSCAN  ( transient elastography)  is a novel and a promising  
approach for staging hepatic fibrosis. It rapidly and non invasively 
measures the mean hepatic tissue stiffness. 
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Using a probe, which includes an ultrasonic transducer , a vibration 
of low frequency ( 50 MHz) and amplitude is transmitted into the liver. 
The vibration wave induces an elastic shear wave that propagates through 
the organ. The velocity of this wave as it passes through liver correlates 
directly with tissue stiffness. The harder the tissue, the faster  the shear 
wave propagates. Results are expressed in kilo pascals. 
Fibroscan measure liver stiffness of a volume that is approximately 
a cylinder of 1 cm diameter and 5 cm long, which is 100 times greater in 
size of a standard liver biopsy and thus may be more representative of 
liver parenchyma. 
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FIBROSCAN 
 
 
XL PROBE- NEW ADVANCEMENT 
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MECHANISM OF FIBROSCAN 
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ADVANTAGES  
 
• The scan can be easily performed. 
• It is an inexpensive tool. 
• It does not produce any side effects 
• Patient  may feel the pressure of the probe without anticipated pain. 
• The measurement can be reproducible  
• It is independent of the operator. 
 
LIMITATIONS 
The following parameters may hamper the accuracy of the test 
• Obesity 
• Tense ascites 
• Narrow intercostal space 
  RATIONALE OF FIBROSCAN 
 Fibroscan may be used as a indirect tool to assess the presence of 
portal hypertension. 
 Presence of large esophageal varice s can be predicted  by 
measuringthe lver stiffness  in cirrhotic patients  and may assist  in 
selecting  patients for OGDscopy screening. 
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 Foucher et al studied the importance  of  TE for detecting large 
esophageal varices and the  variceal hemorrhage risk in patients with 
cirrhosis. For stage 2  esophageal varices the LS value was 27.5 kPa and 
for stage 3 it was around 62.7 kPa. 
 It was concluded that  fibroscan may be of great use in the 
management and follow up of the patient. 
 Klibansky et al was successful in describing a valuable application 
of fibroscan to predict clinical outcomes in cirrhosis. 
 Castera et al had a conclusion that fibroscan can be a promising 
tool for prediction of esophageal varices and discriminates the patients 
with large esophageal varices with the risk of bleeding. However optimal 
cut offs may vary from study to study an optimal fibroscan cut off 
remains to be defined. 
 Sporea et al ., studied 1000 patients with cirrhosis and the optimum 
cut off value for presence of varices was 31 kPa and for bleding cut off 
was 50.7 kPa. 
 Vizzutti et al  showed a cut off value of 17.6 kPa for prediction of 
varices. 
 Based on these studies we wanted to evaluate for the prediction of 
esophageal varices in chronic liver disease using fibroscan and other 
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parameters like platelet count and spleen size  taking into the ratio of 
platelet count is to the spleen diameter.  
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MATERIALS AND METHODS 
 
Study design : Observational study 
Study centre :  Madras medical college & Rajiv Gandhi Government 
General Hospital Chennai-600003 
Duration of the study : 6 months 
Ethics Committee Approval : Obtained 
Inclusion criteria:  Newly diagnosed chronic liver disease patients 
irrespective of the etiology 
Exclusion criteria  
• Patients who received endoscopy previously for variceal 
bleeding 
• Patients with hepatocellular carcinoma 
• Patient who has undergone surgical intervention for portal 
hypertension 
• Patients with Post hepatic causes of cirrhosis  
Sample size : 50  
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INVESTIGATIONS  DONE 
 
• Complete  hemogram    
• Hemoglobin ( g/ dl) 
• Total count ( cells/ cumm) 
• Differential count 
• RBCs 
• Platelet count 
• MCV 
• MCHC 
• PCV 
 
Renal function tests 
• Blood urea 
• Serum creatinine 
• Plasma glucose  
 Liver function tests 
• Total bilirubin 
• Direct bilirubin 
• SGOT 
• SGPT 
• ALP 
• Total protein 
• Serum albumin 
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USG abdomen  
Spleen size 
Ascites : yes/ no 
Chest radiography 
Fibroscan  
Upper GI Endoscopy 
 Spleen platelet ratio  
 
PROCEDURE 
Fifty patients with chronic liver disease , attending medical ward, 
hepatology ward and out patient department of Rajiv Gandhi Government 
General hospital , Chennai, between the month of March 2014  to 
September 2014  were selected for observational study, based on the 
inclusion and exclusion criteria. 
All patients in the study underwent a full clinical examination. 
Clinical history and physical examination findings were recorded with 
particular attention to present or previous history of hemetemesis, 
malena, bleeding per rectum, bleeding diathesis, alcohol intake, blood 
transfusion, intake of hepatotoxic drugs, exposure to sexually transmitted 
diseases, iv drug abuse, jaundice, anaemia, splenomegaly and 
encephalopathy. 
77 
 
All patients underwent biochemical tests, such as liver function 
tests, complete hemogram, renal function tests, prothrombin time, 
ultrasonography of the abdomen to confirm the presence of cirrhosis and 
to record spleen bipolar diameter, portal vein size, ascites and presence of 
collaterals.  
Fibroscan was done  to assess the stiffness of liver.  
Fibroscan is done using  in the morning with patients in a fasting 
state. 
Measurements were  performed using XL probe on the right lobe 
of the liver  through  through intercostals spaces on patient lying in the 
dorsal decubitus position with right arm in maximal abduction. The tip of 
the probe transducer was placed on skin between the ribs at the level of 
right lobe of the liver. Ten successful measurements are taken on each 
patient. Success rate was calculated as the ratio of number of successful 
measurements over the total number of acquisitions of which  60% is 
considered  as best. 
Upper GI endoscopy was done in all patients to confirm the 
presence of varices and also to grade them. 
Data were collected in a pre determined proforma and results were 
analysed using software statistical package student version. Continous 
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variables were analysed using t- test and categorical variables by chi 
square test . pearson correlation was used to find the correlation between 
two variables.The following results were obtained.  
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OBSERVATION AND RESULTS 
 
SEX DISTRIBUTION 
 
SEX NUMBER OF PATIENTS PERCENTAGE 
Male 42 84 
Female 8 16 
Total 50 100 
 
 
 
SEX DISTRIBUTION 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
Male Female Total
NUMBER OF PATIENTS
NUMBER OF PATIENTS
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PRESENCE OF VARICES AMONG PATIENTS 
 
 Frequency Percent 
Positive 44 88.0 
 Negative 6 12.0 
 Total 50 100.0 
 
 
 
PRESENCE OF VARICES AMONG PATIENTS 
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GRADE OF VARICES 
 
 Frequency Percent 
 
 
Grade 0 6 12.0 
 
  
Grade I 23 46.0 
 
  
Grade II 13 26.0 
 
  
Grade III 8 16.0 
  Total 50 100.0 
    
 
 
GRADE OF VARICES  AMONG PATENTS 
 
 
 
 
Sex
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C
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DESCRIPTIVE STATISTICS 
 
  N Range 
Minim
um 
Maxim
um Mean 
Std. 
Deviation 
Age in years 50 46 18 64 45.28 10.852 
HB% 50 9.8 5.1 14.9 11.030 2.1879 
PT 50 45.0 14.0 59.0 23.850 8.4692 
INR 50 2.98 1.05 4.03 1.8920 .64632 
S.Bilirubin 50 36.9 .3 37.2 7.186 9.1926 
S.Albumin 50 2.6 1.5 4.1 2.452 .4665 
Platelet Count 50 334000 19000 353000 101852.00 62533.071
Spleen Bipolar 
Diameter 50 94 78 172 122.00 29.491 
PC/SD Ratio 50 3379.21 150.79 
3530.0
0 
915.94
12 659.15656
Fibroscan L.S 50 60.9 14.1 75.0 42.421 17.1934 
Valid N (listwise) 50           
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COMPARISON BETWEEN SEX AND PRESENCE OF VARICES 
 
  Varices Total P value 
  Positive Negative   
Sex Male Count 36 6 42  
 
 
 
 
0.254 
 
( NOT 
SIGNIFICA
NT) 
    % 
within 
Sex 
85.7% 14.3% 100.0% 
    % 
within 
Varices 
81.8% 100.0% 84.0% 
  Female Count 8 0 8 
    % 
within 
Sex 
100.0% .0% 100.0% 
    % 
within 
Varices 
18.2% .0% 16.0% 
Total Count 44 6 50 
  % 
within 
Sex 
88.0% 12.0% 100.0% 
  % 
within 
Varices 
100.0% 100.0% 100.0% 
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COMPARISON BETWEEN SEX AND PRESENCE OF VARICES 
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PC/SD RATIO & FIBROSCAN L.S VALUE 
 
  Varices N Mean 
Std. 
Deviation P value 
PC/SD 
Ratio 
Positive 
44 
758.73
15 
419.39005
<0.001 
(highly 
significant) 
 
  Negative 
6 
2068.8
125 
965.87447
Fibroscan 
L.S 
Positive 
42 45.440 16.2323 
<0.001 
(highly 
significant) 
 
  Negative 
6 21.283 2.3267 
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PLATELET COUNT AND PRESENCE OF VARICES 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 N Mean 
Std. 
Deviation 
Minim
um 
Maxim
um 
P value 
Grade 0 
6 
190000
.00 
104370.49
4 
95000 353000 
 
0.001 
( Significant) Grade I 
23 
97634.
78 
42005.785 31000 179000 
Grade II 
13 
85461.
54 
49765.476 19000 205000 
Grade III 
8 
74500.
00 
41572.656 31000 163000 
Total 
50 
101852
.00 
62533.071 19000 353000 
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SPLEEN BIPOLAR DIAMETER  AND PRESENCE OF VARICES 
 
 
  N Mean 
Std. 
Deviation Minimum Maximum 
 
P value 
Grade 0 6 89.33 14.679 78 114  
 < 0.001**  
(Highly 
Significant) 
Grade I 23 110.35 25.906 78 170 
Grade II 13 139.38 20.468 96 164 
Grade III 8 151.75 13.156 136 172 
Total 50 122.00 29.491 78 172 
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PC/SD RATIO AND PRESENCE OF VARICES 
  
 N Mean 
Std. 
Deviation Minimum Maximum 
P value 
Grade 0 6 2068.8125 965.87447 1186.05 3530.00 < 0.001** 
 
(Highly 
Significant)
 
Grade I 23 908.6580 380.25870 182.35 1864.58 
Grade II 13 650.6636 458.42174 150.79 1863.64 
Grade III 8 503.3028 309.25844 201.30 1181.15 
Total 50 915.9412 659.15656 150.79 3530.00 
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FIBROSCAN L.S AND PRESENCE OF VARICES 
  
 N Mean 
Std. 
Deviation Minimum 
Maxim
um 
P VALUE 
Grade 0 6 21.283 2.3267 18.0 25.1  
<0.001** 
 
(Highly 
Significant) 
Grade I 21 33.867 8.1293 14.1 48.2 
Grade II 13 48.277 9.2487 23.8 57.2 
Grade III 8 71.213 5.6529 59.3 75.0 
Total 48 42.421 17.1934 14.1 75.0 
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FIBROSCAN L.S AND VARIOUS GRADES OF VARICES 
 
(I) Grade of 
Varices 
(J) Grade of 
Varices Mean Difference (I-J) 
P.Value. 
Highly 
Significant 
Grade 0 Grade I -12.583(*) .005 
  Grade II -26.994(*) .000 
  Grade III -49.929(*) .000 
Grade I Grade 0 12.583(*) .005 
  Grade II -14.410(*) .000 
  Grade III -37.346(*) .000 
Grade II Grade 0 26.994(*) .000 
  Grade I 14.410(*) .000 
  Grade III -22.936(*) .000 
Grade III Grade 0 49.929(*) .000 
  Grade I 37.346(*) .000 
  Grade II 22.936(*) .000 
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SENSITIVITY AND SPECIFICITY FOR FIBROSCAN L.S CUT 
OFF > 32kPa Versus * VARICES 
 
  
 
  Varices Total P  
Value   Positive Negative  
Fibroscan 
L.S > 32 
Positive Count 35 0 35 
    % within 
Fibroscan 
L.S > 32 
100.0% .0% 100.0% 
 
 
 
 
 
 
 
0.001 
 
    % within 
Varices 79.5% .0% 70.0% 
  Negative Count 9 6 15 
    % within 
Fibroscan 
L.S > 32 
60.0% 40.0% 100.0% 
    % within 
Varices 20.5% 100.0% 30.0% 
Total Count 44 6 50 
  % within 
Fibroscan 
L.S > 32 
88.0% 12.0% 100.0% 
  % within 
Varices 100.0% 100.0% 100.0% 
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SENSITIVITY AND SPECIFICITY FOR FIBROSCAN L.S CUT 
OFF > 32kPa Versus * VARICES 
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SENSITIVITY AND SPECIFICITY FOR PC/SD RATIO   
 
    Varices Total 
    Positive Negative   
PC/SD 
Ratio 
Positive Count 
30 0 30
    % within 
PC/SD 
Ratio 
100.0% .0% 100.0%
    % within 
Varices 
68.2%
Sensitivity
.0% 60.0%
  Negative Count 14 6 20
    % within 
PC/SD 
Ratio 
70.0% 30.0% 100.0%
    % within 
Varices 
31.8%
100.0% 
Specificity 
40.0%
Total Count 44 6 50
  % within 
PC/SD 
Ratio 
88.0% 12.0% 100.0%
  % within 
Varices 
100.0% 100.0% 100.0%
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SENSITIVITY AND SPECIFICITY FOR LS VALUE 29.7 kPa                    
 
 
 
 
  
Varices Total 
Positive Negative   
Fibroscan 
L.S > 
29.7 
Positive Count 
36 0 36 
    % within 
Fibroscan 
L.S > 
29.7 
100.0% .0% 100.0%
    % within 
Varices 
81.8% 
Sensitivity .0% 72.0% 
  Negative Count 8 6 14 
    % within 
Fibroscan 
L.S > 
29.7 
57.1% 42.9% 100.0%
    % within 
Varices 18.2% 
100.0% 
Specificity 28.0% 
Total Count 44 6 50 
  % within 
Fibroscan 
L.S > 
29.7 
88.0% 12.0% 100.0%
  % within 
Varices 100.0% 100.0% 100.0%
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FOR A  CUT OFF VALUE OF 29.7 kPa 
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PC/SD RATIO CUT OFF VALUE < 915.94 * VARICES 
 
  
 
    Varices Total P 
Value     Positive Negative   
PC/SD 
Ratio < 
915.94 
Positive Count 
30 0 30 
    % within 
PC/SD 
Ratio < 
915.94 
100.0% .0% 100.0% 
0.002 
    % within 
Varices 
68.2% 
Sensitivity .0% 60.0% 
  Negative Count 14 6 20 
    % within 
PC/SD 
Ratio < 
915.94 
70.0% 30.0% 100.0% 
    % within 
Varices 31.8% 
100.0% 
Specificity 40.0% 
Total Count 44 6 50 
  % within 
PC/SD 
Ratio < 
915.94 
88.0% 12.0% 100.0% 
  % within 
Varices 100.0% 100.0% 100.0% 
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         PC/SD RATIO CUT OFF VALUE < 915.94 * VARICE 
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DISCUSSION 
 
Variceal  bleeding  is the most important complication of cirrhosis. 
The first crucial step in prevention is the identification of patients 
who are at risk of bleeding by the use of OGD scopy , to subject them for 
prophylactic therapy.  Since a variable proportion of patients will not 
have varices, screening of all patients with cirrhosis with upper GI 
endoscopy implies a number of unwanted OGD scopy which increase the 
work load of endoscopy units. In addition recommendations are limited 
on the compliance with endoscopic screening. Prediction of the presence 
of varices by non invasive modes would allow us to restrict the 
performance of endoscopy to those patients with ahigh probability of 
having the varices. 
Our  sample size consisted of fifty patients of whom 42 were male 
and 8 were female. Male constitute around 84% and female patients 
constitute about 16%. 
Distribution of grades of varices was studied in various age group 
and no significant correlation was found. 
No significant gender difference in the distribution of grade of 
varices was found. 
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Signs of liver cell failure was found in 48 of our patients 
constituting around 96% of the total. 
Ascites was found in 9 of our patients constituting around 18% of 
the total. 
Encephalopathy was present in 6 of our patients constituting about 
12% of the total. Our study could not find any significant association 
between hepatic encephalopathy and varices. 
Varices was positive in 44 of the patients constituting about 88% of 
the total and remaining 12% was found negative for varices. 
Among the patients with presence of varices 23 had grade 1 varices 
constituting 46% of the total. 13 patients had grade 2 varices comprising 
26% of the total. 8  patients had grade 3 varices comprising 16% of the 
total. 
Child pugh scoring : 15 patients came under the category B  and 35 
patients came under category C. Relationship between non invasive 
parameters like serum bilirubin, serum albumin, hemoglobin, platelet 
count, spleen bipolar diameter to the presence of varices was studied. 
Among these only platelet count ( P=0.001) and SD( P = 0.003) had 
statistical  significance. 
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The results indicating the relevance of platelet count are on par 
with studies by thomplos et al (2003), madhotra et al (2002) , pilette et al 
(1999), shepis et al (1999), zaman et al(1999). 
Studies by chalasani et al (1999), sanjay kumar et al (2006) , torres 
et al (1996) state that splenomegaly is an independent predictor of 
presence of varices. 
PC/ SD RATIO INFERENCE 
Patients were categorized in two groups based on cut off value of 
909 for PC/SD ratio. Its relation to the grade of varices was studied. A 
significant difference between the presence or absence of varices and 
ratio of PC/SD of 909  was observed. (P =0.001) . This finding is in 
agreement with study by Gianni et al (2003). The use of platelet count / 
spleen diameter ratio overcomes the fallacy of  using platelet count alone 
in predicting esophageal varices for the reason that platelet count may 
decrease in chronic liver disease due to several other factors. This ratio is 
introduced to take into consideration the decrease in platelet count which 
most likely depends on hypersplenism caused by portal hypertension. 
Performing unwanted OGD scopy in all patients can be avoided if 
we take PC/SD ratio cut off  909, without running the risk of missing 
cases with esophageal varices. 
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Although thomopolos et al (2003) have put forth ascites as an 
independent predictor of presence of large varices, our study does not 
demonstrate a statistically significant correlation between presence and 
grade of varices and ascites. 
 
FIBROSCAN INFERENCE 
In our study all the patients were subjected to fibroscan and the 
correlation with the presence of esophageal varices was attempted.  
We found that there was a statistically significant association 
between fibroscan value and the presence of varices represented by P = 
0.001.  
 
The mean  fibroscan liver stiffness values are as follows 
No varices             -       21.28±2 kPa 
Grade 1 varices    -        33.867±8 kPa 
Grade 2 varices    -       48.27± 9 kPa 
Grade 3 varices   - 71.21±5 kPa 
 
These values are on par with fibroscan study by Iulia et al (2008) . 
based on this study For a cut off value of 32 kPa  the sensitivity and 
specificity was 79.5% and 100% respectively, which when compared to 
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study by Iulia et al where the values were found to be 58.44 and 72.22 % 
respectively. 
For a cut off value of 62.8 kPa the sensitivity and specificity are 
15.9% and 100% when compared to this reference study where the values 
of 24.6 % and 97.22 %. when a cut off value of 29.7kPa  applied the 
sensitivity and specificity obtained are 81.8% and 100% respectively.  
These values when compared  on par with study by Mohamed said 
et al (2013) which were found as 95% and 77.3% for sensitivity and 
specificity.  
For a cut off value of 42.42 kPa  ( mean fibroscan value)applied, 
the sensitivity is 50% and specificity is 100% Castera et al stated the 
optimal cut off vary from study to study, therefore optimal fibroscan cut 
off remains to be defined. 
A study by Foucher et al, the cut off values for presence of grade 
2/3 varices were 27.5kPa and 62.7 kPa respectively. 
A study by Klibansky et al concluded that fibroscan as a more 
useful tool assessing clinical outcome like varices in cirrhotic patients. 
In a study by Vizzuli et al a cut off value of 17 kPa was used for 
prediction of varices which when compared to our study and other studies 
it was  found to be lower value cut off. 
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Kazemi et al concluded that fibroscan has the highest significant 
value followed by platelet count/ splenic diameter ratio for the detection 
of presence of varices. 
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SUMMARY AND CONCLUSION 
SUMMARY 
 
Fifty patients with newly diagnosed cirrhosis without prior history 
of bleeding were subjected to clinical evaluation. All patients underwent 
biochemical tests, such as liver function tests, complete hemogram , renal 
function tests, prothrombin time, ultrasonography of the abdomen to 
confirm the presence of cirrhosis and to record the spleen bipolar 
diameter, ascites and the presence of collaterals. 
Fibroscan ( transient elastography) was done to assess the liver 
stiffness values. Upper GI endoscopy was done in all patients to confirm 
the presence of varices and also to grade them. We tried to identify non 
invasive parameters for prediction of esophageal varices in chronic liver 
disease patients. We assessed the role of platelet/ spleen diameter ratio 
and fibroscan for predicting esophageal varices in cirrhotic patients. 
Presence of varices increase as patients progress to decompensated 
stage ( child pugh score B & C ) . 
Decrease in platelet count was found to be an predictor of 
esophageal varices in patients with cirrhosis. 
Ultrasound parameter spleen bipolar diameter also predicts the 
presence of esophageal varices. 
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When a cut off value of platelet count/ spleen diameter of ≤ 909 
was employed in order to take into consideration the decrease in platelet 
count due to hypersplenism; it was found to be a good predictor of 
presence of esophageal varices. 
The sensitivity of PC/SD ratio of ≤ 909 in predicting the presence 
of esophageal varices was 68.2% and for a ratio of 915.94(mean) it is 
found to be 62.8%. 
Fibroscan measurement of liver stiffness value proves to be a 
significant prognostic tool for the prediction of esophageal varices. 
A significant statistical association was observed between 
fibroscan values and the prediction of esophageal varices . ( P = 0.001) 
For a cut off value of 32 kPa the sensitivity and specificity are 79.5%  and 
100% respectively.  
For a cut off value of 62.8 the specificity was 100% and sensitivity 
was 15.9%. 
 
 
 
 
 
 
107 
 
CONCLUSION 
 
Combining  these two non invasive parameters , FIBROSCAN and 
ratio of PLATELET COUNT/ SPLEEN DIAMETER  in patients with 
chronic liver disease can increase the reliability of predicting the  
presence of esophageal varices. Their use in screening and follow up of 
esophageal varices may substantially reduce the cost of health care and 
discomfort for  patients as well reduce the burden of endoscopy units. 
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LIMITATIONS 
 
1. Small sample size 
2. Prospective studies were not done to validate the role of predictive 
parameters 
3. Although we could show that combining the two non invasive 
parameters increased the percentage of varices being detected, the 
combined sensitivity could not be calculated. 
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PROFORMA 
 Name :      
Age:                       
Sex: 
 
Occupation :     Residence : 
 
Clinical history: (including duration of CLD) 
 
Pattern of consumption of alcohol: 
 
Examination findings : 
 
Basic investigation : CBC, LFT, RFT  Viral markers:  
HbsAg 
        Anti HCV 
CBC 
RBC   
TC DC   N         L 
 E B 
HB   
ESR   
PLATELET  
RFT 
Glucose  mg/dl 
Urea  mg/dl 
Creatinine  mg/dl 
Na+  mEq/l 
K+  mEq/l 
116 
 
 
LFT 
Total bilirubin  mg/dl 
Direct bilirubin  mg/dl 
SGOT  U/l 
SGPT  U/l 
ALP  U/l 
Total protein  g/dl 
Albumin  g/dl 
 
USG  abdomen : 
 
Spleen size :      ascites: yes/no 
 
CXR 
 
 
Fibro Scan in pKa Values 
 
Endoscopy findings  
 
Spleen platelet ratio  
 
 
  
117 
 
PATIENT CONSENT FORM 
 
 
Study Title : “PREDICTION OF ESOPHAGEAL 
VARICES IN CHRONIC LIVER DISEASE 
PATIENTS BY USING FIBROSCAN, 
SPLEEN SIZE AND PLATELET COUNT” 
 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
 
Name :  
 
Age/Sex :  
 
Identification 
Number 
:  
 
 
 
Patient may check (☑) these boxes 
 
The details of the study have been provided to me in writing and explained to 
me in my own language 
 
 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights 
being affected. 
 
 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. 
 
 
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I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. 
 
 
I hereby consent to participate in this study. 
 
 
I hereby give permission to undergo complete clinical examination, diagnostic 
tests including hematological, biochemical tests and radiological tests. 
 
 
 
 
Signature/ Thumb impression                                  Signature of the 
investigator 
 
Patient’s name and address                                        Study Investigator’s 
name 
 
 
                                                                                
Dr.M.PRASANNAKUMAR 
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